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Targeting epigenetic proteins is a rapidly growing area for medicinal chemistry and 
drug discovery. Recent years have seen an explosion of interest in developing small 
molecules binding to bromodomains, the readers of acetyl-lysine modifications. A 
plethora of co-crystal structures has motivated focused fragment-based design and 
optimization programs within both industry and academia. These efforts have yielded 
several compounds entering the clinic, and many more are increasingly being used as 
chemical probes to interrogate bromodomain biology. High selectivity of chemical 
probes is necessary to ensure biological activity is due to an on-target effect. Here, 
we review the state-of-the-art of bromodomain-targeting compounds, focusing on 
the structural basis for their on-target selectivity or lack thereof. We also highlight 
chemical biology approaches to enhance on-target selectivity.
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Many physiological and pathological cellular 
processes are regulated by epigenetic mecha-
nisms as a response to environmental stim-
uli [1]. It is well known that epigenetic regula-
tion is controlled by chemical modifications 
on DNA and on post-translational modifica-
tions (PTMs) on histones, including acetyla-
tion, methylation and phosphorylation [2,3]. 
These chemical modifications on the histone 
amino acids are recognized by specific multi-
domain proteins able to write, read or erase 
them, and deregulation of these processes has 
been associated to disease [4–6]. Cancer was 
the first human disease linked to epigenetics. 
In 1983, Feinberg et al. found that genes of 
colorectal cancer cells were hypomethyl-
ated compared with normal tissues [7]. Since 
then, efforts have been devoted to increase 
knowledge in epigenetics and in particular 
to exploit understanding of these processes 
in order to develop new targeted molecular 
therapeutics [8,9].
Acetylation of the e-amino group of lysine 
residues (KAc) is one of the most common 
modifications of histone tails [10,11]. Acety-
lation levels are reversibly maintained by 
histone acetyltransferases (HAT) and his-
tone deacetylases (HDAC) that respec-
tively write and erase this PTM [12]. HATs 
and HDACs are often deregulated in dis-
eases through mechanisms that include 
aberrant expression levels, the occurrence 
of mutations as well as truncations, and 
chromosomal rearrangements [13]. From a 
drug discovery point of view, to date only 
a very limited number of HAT inhibitors 
have been described and the investigation 
of HAT inhibitors has been mostly lim-
ited to in vitro studies of growth inhibition 
of cell lines [14]. In contrast, several small 
molecules able to inhibit HDAC catalytic 
activity have been discovered and have also 
entered clinical trials with five examples 
already approved [15]. HDACs are to date 
Selectivity on-target of bromodomain 
chemical probes by structure-guided 
medicinal chemistry and chemical biology
Carles Galdeano1,2 & Alessio 
Ciulli*,1
1Division of Biological Chemistry & Drug 
Discovery, School of Life Sciences, 
University of Dundee, James Black Centre, 
Dow Street, Dundee, DD1 5EH, UK 
2Institut de Biomedicina de la Universitat 
de Barcelona (IBUB) & Departament 
de Fisicoquímica, Facultat de Farmàcia, 
Universitat de Barcelona, Av. Joan XXIII 
s/n, 08028 Barcelona, Spain 
*Author for correspondence:  
Tel.: +44 1382 386230 
Fax: +44 1382 386373 
a.ciulli@dundee.ac.uk
For reprint orders, please contact reprints@future-science.com
Figure 1. BET bromodomain inhibitors. Representation of the chemical structure of (+)-JQ1, I-BET762, CPI-0610,  
RVX-208 and OTX015.
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the most explored epigenetic drug target family by 
the pharmaceutical industry [16].
In contrast, much less has been known of the read-
ing process of acetylation marks in histones, and tar-
geting protein interactions mediated by epigenetic 
readers of this PTM had remained largely unexplored 
until recently. However, this suddenly changed in 2010 
with the publication of potent and selective triazolo-
diazepine-based inhibitors of Bromo and Extra-Ter-
minal domain (BET) proteins, (+)-JQ1 and I-BET762 
(Figure 1) [17,18], which were shown to have in vivo on-
target activity in models of NUT midline carcinoma 
and inflammation, respectively. BET inhibitors bound 
to highly conserved regions of BET proteins, called 
bromodomains, which were known to recognize the 
KAc modification in histones and other substrates.
These two groundbreaking discoveries demon-
strated the high druggability of the bromodomain-
KAc interaction and motivated further drug develop-
ment efforts in this area. Since then, there has been 
an explosion of small molecules discovered or designed 
to target BET bromodomains as well as other bromo-
domains in the human phylogenetic tree. This has in 
part been facilitated by the high ‘ligandability’ toward 
fragment-like molecules, including small organic co-
solvents such as DMSO and NMP [19]. This propen-
sity to ligand binding has aided identification of high 
ligand efficiency hits from fragment screening cam-
paigns that could be readily optimized for potency. In 
addition to providing leads that could be developed 
in drug discovery programs, these new molecules 
could be used to elucidate the biological function of 
bromodomains and their importance as therapeu-
tic targets, in other words, as high-quality epigenetic 
chemical probes [20,21]. However, the high structural 
conservation of bromodomains pose a significant chal-
lenge toward developing suitable single-target selective 
inhibitors. Lack of selectivity poses a potential limita-
tion to bromodomain inhibitors as chemical probes as 
it may confound the association of the cellular activity 
of a given probe to a particular bromodomain target. 
This has spurred mounting interest in developing more 
selective compounds.
Here we review recent advances to understand and 
exploit target selectivity of bromodomain chemical 
probes. We exemplify these efforts with case studies 
taken not only from the BET bromodomain subfam-
ily but also from other bromodomain classes, as well 
as from studies identifying potential roles of bromo-
domains as off-targets, for example, of protein kinase 
inhibitors. We also highlight new developments in 
chemical biology approaches to enhance on-target 
selectivity of bromodomain probes and rationalize and 
alleviate off-target effects.
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Bromodomains & bromodomain-containing 
proteins: structure, inhibition by chemical 
probes & emerging role as drug targets
Bromodomains are an evolutionarily conserved family 
of ∼110 amino acid modules found in histone acetyl 
transferases and other chromatin-associated proteins 
and transcriptional regulators [22]. The human genome 
encodes 46 of such bromodomain-containing proteins 
(BCPs) [23]. Each of the 46 proteins contains one to 
six bromodomains, giving a total number of 61 unique 
individual human bromodomain sequences. Based 
on sequence similarity, the whole human family of 
bromodomains can be divided into eight diverse sub-
families (group I–VIII) each containing at least three 
bromodomains and comprising proteins of diverse 
functions [24]. While most BCPs recognize KAc marks 
on histone tails, evidence suggests that bromodomains 
also are able to bind to acetylated proteins beyond 
histones [19]. An example of PTM recognition in non-
histone substrate is the HIV-1 Tat, which gets acety-
lated at position K50 and this allows it to associate to 
PCAF via recognition by the PCAF bromodomain [25]. 
Another example is in the p53 DNA damage response 
signal cascade, where acetylation of K382 on p53 
enables the recruitment of transcriptional co-activator 
CREBBP via its bromodomain and ultimate activation 
of pro-apoptotic genes [26,27].
Despite their low overall sequence identity (∼21%) 
bromodomains share a conserved fold comprising a 
bundle of four α-helices (named αZ, αA, αB and αC) 
linked by more diverse loop regions (Figure 2A). Two 
of these loops (ZA and BC) that make up the mouth 
of the KAc binding site show large sequence variations 
and contribute to substrate specificity [28,29]. Crystal 
structures with bound histone and substrate peptides 
have shown that KAc is recognized within a hydro-
phobic pocket and anchored by forming a conserved 
hydrogen bond between its side chain amide group 
and the side chain amide of a highly conserved Asn 
residue [30]. In addition, a water-mediated hydrogen 
bond is formed with the hydroxyl group of a conserved 
Tyr residue. Both residues are located at the bottom 
of the ZA loop of bromodomains (Figure 2B) [31]. 
Another characteristic feature at the base of the KAc 
recognition pocket is the presence of a network of 
water molecules that forms hydrogen bonds with the 
carbonyl group of the substrate KAc, forming the 
ZA channel (Figure 2B). Finally, in many bromodo-
mains, including the BET subfamily members and a 
few others, a conserved stretch of three amino acids 
known as the ‘WPF shelf ’ is found (Figure 2C). The 
presence or absence of the WPF shelf can be explored 
to achieve selectivity between BET and non-BET 
bromodomains [32].
Bromodomain-containing proteins (BCPs) are often 
deregulated in disease, and their bromodomains appear 
to have crucial roles to disease mechanism. Among the 
classes of BCPs that have been linked to disease are 
transcriptor co-regulators (e.g., BET protein BRD4 
and ATAD2), transcriptional repressors (e.g., BAZ2A, 
also known as TIP5), chromatin-remodeling factors 
(e.g., BAZ1A, BPTF, CECR2), histone acetyltrans-
ferases (e.g., CREBBP and EP300) and E3 ubiquitin 
ligases (e.g., TRIM24) among others. Association of 
the role of many BCPs in disease has spurred the devel-
opment of bromodomain inhibitors for drug discov-
ery purposes [23]. Over the past 5 years, many inhibi-
tors that target the BET subfamily of bromodomains 
have emerged. The BET subfamily, which comprises 
four members in humans (BRD2, BRD3, BRD4 and 
BRDT), take their name from the presence of two 
related tandem bromodomains named BD1 and BD2, 
able to specifically recognize different acetylation pat-
terns in H3 and H4 histone tails [33]. Although BET 
bromodomains have a highly similar structural archi-
tecture, their function as individual domains is likely 
to be distinct. BET proteins are also likely to have 
distinct physiological roles, forming different protein–
protein interactions (PPIs) and controlling specific 
regulatory networks [34]. For example, BRD4 acts as a 
transcription co-regulator [35,36]; BRD3 binds to acety-
lated GATA1 and regulates erythroid target genes [37]; 
while BRD2 is involved in cell-cycle progression [38], 
among other processes [39].
To date, ten compounds blocking PPIs of BET 
bromodomains have entered clinical trials. One of 
them, RVX-208 (Figure 1, also named apabetalone 
and RVX000222) has reached Phase III clinical tri-
als in autumn 2015 (NCT01728467), being the most 
advanced one. RVX-208, developed by Resverlogix 
Corp., has been evaluated in a total of seven clinical 
trials for the treatment of atherosclerosis and associ-
ated cardiovascular disease. In clinical Phase II, RVX-
208 increased HDL-cholesterol and apolipoprotein 
A1 levels, as well as decreased the incidence of major 
adverse cardiac events (MACE). Additionally, reduc-
tion of MACE was accentuated in patients with diabe-
tes mellitus. Three more BET bromodomains inhibi-
tors have also reached Phase II clinical trials (OTX015, 
BMS-9861158 and GSK525762). OTX015 (Figure 1), 
developed by OncoEthix and Merck is involved in four 
different clinical trials for the treatment of acute leuke-
mia and hematologic malignancies (NCT01713582), 
advanced solid tumors (NCT02259114), recurrent 
gliobastoma multiforme (NCT02296476) and in com-
bination with azacitidine in patients in newly diagnosed 
acute myeloid leukemia that are not candidates for 
standard intensive induction therapy (NCT02303782). 
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BMS-986158 (structure undisclosed) has been tested 
for multiple cancer indications alone and together 
with paclitaxel (NCT02419417). Finally, GSK525762, 
also known as I-BET762 (Figure 1) [18] is involved in 
two clinical trials: one to investigate safety, pharma-
cokinetics, pharmacodynamics and clinical activ-
ity in patients with NUT midline carcinoma and 
other cancers (NCT01587703) and a second one for 
patients with solid tumors with hematologic malignan-
cies (NCT01943851). In addition to these four mol-
ecules, six other BET inhibitors have recently entered 
Phase I clinical trials and are being studied for both solid 
tumors and hematological malignancies: two com-
pounds with a very similar structure to (+)-JQ1, TEN-
010 [32] (NCT02308761, NCT01987362) and CPI-
0610 [40] (Figure 1, NCT01949883, NCT02157636, 
NCT02158858); GS-5829 (structure undisclosed, 
NCT02392611, NCT02607228); BAY1238097 (struc-
ture undisclosed, NCT02369029); ABBV-075 (struc-
ture undisclosed, NCT02391480); and INCB054329 
(structure undisclosed, NCT02431260).
Despite achieving several compounds in clinical 
trials, the development of BET inhibitors as chemi-
cal probes of individual BET proteins has remained a 
major challenge, due to lack of single target selectiv-
ity. Chemical probes are small molecules that elicit a 
cellular response by interacting with a specific protein 
inside the cell. In doing so, chemical probes can be 
used to explore the role of that particular protein in 
biological systems [41]. High-quality chemical probes 
must fulfill certain requirements that drugs do not 
necessarily do. Drugs must be safe and effective at 
treating disease, in contrast chemical probes must 
have a defined mechanism of action and should be as 
selective as possible, ideally for a single target [21,42]. 
The recent Chemical Probes Portal [43] provides infor-
mation and guidelines on the criteria for establishing 
such high-quality chemical probes [21]. The web por-
tal already contains several bromodomain inhibitors 
and could be an invaluable tool for the scientific com-
munity working in this field.
The problem of chemical probe on-target 
selectivity in bromodomains
The high similarity within the different subfamilies of 
bromodomains and in particular at the level of their 
KAc binding sites poses inherent challenges for the 
development of bromodomain inhibitors as selective 
chemical probes. It is critical that a chemical probe 
molecule has a high degree of selectivity for one bro-
modomain over the other bromodomains to ensure 
that biological insights can be confidently ascribed to 
the function of the particular bromodomain of inter-
est. Although for some subfamilies very high affinities 
have been described with compounds able to bind to 
bromodomains in the nanomolar range, achievement 
of exquisitely selective molecules for each member of 
the family has proven arduous. BET bromodomains 
are representative examples of this problem. Although 
dozens of potent compounds have been developed in 
the last few years, these are broadly pan-BET selective 
and none of them is able to bind in a selective way to a 
single member of the BET subfamily. In this context, 
several compounds with a poly-pharmacology profile 
for several bromodomains have been described, includ-
ing a compound so-called bromosporine which showed 
reasonable binding affinity for different bromodomain 
family members [44]. Additionally, the availability of 
inhibitors with similar pharmacology but orthogonal 
chemotypes lends confidence to the interpretation of 
the biological activities of the different probes.
The selectivity criteria for chemical probes should 
be more stringent than for drug candidates. For 
drugs, safety is paramount and a level of promiscuity 
may even be beneficial to their efficacy profile and to 
minimize insurgency of drug resistance [21,45]. Guide-
lines on potency and selectivity of chemical probes 
should be considered as flexible and vary depending of 
the target family. For example, Cohen has described 
specific desirable criteria for kinase probes [46]. The 
Structural Genomics Consortium (SGC) has pro-
posed the following criteria for a drug-like compound 
to be nominated as a chemical probe: IC
50
 or K
d
 <100 
nM, selectivity >30-fold over proteins in the same 
family and significant cellular activity below 1 μM, 
matching quite well with the guidelines proposed by 
Workman et al. for high-quality selective chemical 
probes [47]. For other subfamilies outside of BET bro-
modomains, GlaxoSmithKline (GSK) has proposed 
that a minimum selectivity window of 2 and prefer-
ably 3 logs over BET bromodomains is required to 
ensure that an inhibitor has no cross-reactivity and 
that any biological response is not confounded by 
the strong BET-dependent response expected due to 
any BET off-target activity [48]. Large-scale in vitro 
selectivity profiling against other targets is also rec-
ommended, for example, against panels of kinases and 
GPCRs [49].
The typical strategy to gain selectivity in bromodo-
mains has been to start drug discovery campaigns from 
fragments or anchoring scaffolds that bind to the KAc 
site [50], potentially across multiple bromodomains, 
and subsequently focus on optimizing the potency 
and selectivity for each individual bromodomains with 
substituents that interact with the less conserved sites 
at the edges of the KAc binding site. This strategy 
has been successful against several bromodomains, as 
described next.
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Selectivity for BETs versus non-BET 
bromodomains
Selectivity between different subfamilies of bromodo-
mains has been achieved so far with a number of inhibi-
tors. This has been aided by differences in the KAc bind-
ing sites, and by exploiting structural motifs that are 
specific for certain subfamilies. In fact, Vidler et al. [51] 
proposed a classification of human bromodomains 
based on the structural features that vary across the 
KAc binding sites, to complement that derived from 
sequence similarity of the entire domain [24]. In this 
new classification, eight clusters were defined by the 
presence of a unique signature of up to three amino 
acid residues in the binding site, shared by all mem-
bers of each group. This classification should prove use-
ful when determining selectivity of inhibitors and the 
potential to identify possibilities to transfer hit matter 
from one bromodomain to another. Although selectiv-
ity within members of a given group is also desired, this 
section will focus on selectivity across different groups 
with special emphasis on selectivity between BET 
bromodomains and the other subfamilies.
BET bromodomains
Since the pioneering publication of the two triazolodiaz-
epine-based BET-selective inhibitors [17,18], various inhib-
itors of this subfamily have been developed, as extensively 
reviewed elsewhere [23,32,39,50,52–53]. BET bromodomains 
represent a highly druggable subfamily characterized 
by a long and accessible ZA channel and by the above-
mentioned WPF shelf (Figures 2B & 2C). All BET bro-
modomains share this conserved motif, and filling the 
region of space adjacent to the WPF shelf with a small 
molecule has proven critical to achieve high binding 
affinities and to gain selectivity over non-BET bromodo-
mains [54]. In general, BET inhibitors show a very high 
selectivity profile over members of other subfamilies. A 
few compounds have, however, exhibited off-target bind-
ing affinity for the CREBBP bromodomain comparable 
to that for BET bromodomains, for example, PFI-1 
(Supplementary Figure 1) [55], I-BET726 (also named 
GSK1324726A) (Supplementary Figure 1) [56], XD14 
(Supplementary Figure 1) [57,58], the 3,5-dimethylisoxazole 
derivatives (Supplementary Figure 1) [59,60] and a recent 
γ-carboline-based chemical series described by Ran et al. 
(Supplementary Figure 1) [61]. Additionally, a novel series of 
3,5-dimethylisoxazole derivates (Supplementary Figure 1) 
compounds described by McKeown et al. demonstrated 
similar potency for BRD4-BD1 than for the first 
bromodomain of TAF1 [62].
CREBBP/EP300 bromodomains
Achieving selectivity between CREBBP/EP300 and 
the BET subfamily has to date proven difficult as these 
bromodomains all possess long ZA loops bearing simi-
lar residues facing the KAc binding site. However, a 
few residues differ between the CREBBP and the BET 
bromodomains binding sites [60]. First, W81 from the 
top of the WPF shelf of BET bromodomains corre-
sponds to a Leu in the CREBBP, making this part of 
the binding site of CREBBP more suitable in principle 
to accommodate bulkier ligands. Another residue that 
is considered to be key for attaining selectivity toward 
CREBBP is R1173, located at the entrance of the 
binding site of this bromodomain. This residue cor-
responds to D145 in BRD4-BD1. Some selectivity for 
the CREBBP bromodomain has resulted in part from 
exploiting specific cation–π interactions from ligands 
to the R1173 side chain [63–65].
Several CREBBP inhibitors have been described in 
recent years, however, in most cases it has proven dif-
ficult to achieve strong selectivity over BET bromodo-
mains [44,66–69]. The first series of potent inhibitors of 
CREBBP was described by Rooney et al. [63]. The best 
inhibitor reported, (R)-2 (K
d
 = 390 nM by Isothermal 
Titration Calorimetry [ITC], Figure 3B) showed good 
selectivity over a few selected bromodomains but only 
modest selectivity over BRD4-BD1 (3.6-fold) comparable 
to that of compound ischemin (Supplementary Figure 1) 
developed previously [67]. In both cases, x-ray crystal struc-
tures (PDB 4NYW for (R)-2 and 2L84 for ischemin) 
revealed the ability of these compounds to form interac-
tions with the guanidinium group of R1173 in the BC 
loop of CREBBP (Figure 3B).
Hay et al. described SGC-CBP30 (Figure 3B), a 
highly potent (K
d
 = 21 nM by ITC) 3,5-dimethylisoxa-
zole-based inhibitor for CREBBP bromodomain. SGC-
CBP30 displays 40-fold selectivity over BRD4-BD1 
and high selectivity over the other BET bromodomains 
apart from EP300 (K
d
 = 38 nM by ITC) [64,70]. The 
x-ray structure of SGC-CBP30 complexes to CREBBP 
(PDB 4NR7) highlighted the presence of a cation–π 
interaction between the guanidino group of R1173 and 
the aryl ring of the inhibitor, after a structural reor-
ganization induced by the inhibitor (Figure 3B). More 
recently, the same group disclosed an x-ray structure 
with the benzoaxazepine-based inhibitor I-CBP112 
(Figure 3B) co-crystallized with the CREBBP bromo-
domain (PDB 4NR6) [70]. I-CBP112 showed K
d
/IC
50
 
of 170 nM by ITC and Biolayer Interferometry (BLI) 
respectively for the CREBBP bromodomain and a K
d
 
of 625 nM for the EP300 bromodomain. Importantly, 
no interaction was detected by BLI for BDR4-BD1 and 
BRD2-BD2. Again, the aryl group of I-CBP112 inter-
acts with R1173 (Figure 3B). For these two last series 
of selective compounds, the ability to engage in strong 
interaction with R1173 using electron-donating groups 
in the inhibitor aryl ring proved crucial [71].
Figure 3. CREBBP/EP300 bromodomain. (A) Superposition of the x-ray structure of CREBBP (in pink, PDB 4NYW), BRD4-BD1 (in gray, 
PDB 3UVW) and EP300 (in yellow, PDB 5BT3). (B) x-ray structure of the ligands (R)-2 (PDB 4NYW), SGC-CBP30 (PDB 4NR7), I-CBP112 
(PDB 4NR6) and UL04 (PDB 4TQN) bound to CREBBP (in pink). Note that SGC-CBP30 depicts two orientations of the morpholine group 
in the PDB 4NR7.
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The importance of R1173 as a key residue to gain 
selectivity for CREBBP against BET bromodo-
mains was reinforced by a new series of ligands dis-
covered by an in silico approach, with K
d
s down to 
nanomolar range for CREBBP bromodomain [72,73]. 
Selectivity factors of >65, 59 and 48 (compounds 
6, 19 and 21, respectively in the original paper, 
Figure 3B & Supplementary Figure 1) were determined 
as BRD4-BD1-K
d
/CREBBP-K
d
 ratio by competition 
binding [72]. Finite-difference Poisson calculations 
on the minimized x-ray structure of compound 6 (in 
the original paper [72], also named UL04, Figure 3B) 
bound to the CREBBP bromodomain (PDB 4TQN) 
showed that half of the total electrostatic interac-
tion energy is originated by the interaction between 
the carboxylic acid of the compound and the R1173 
of CREBBP (Figure 3B). Although high selectivity 
over BET bromodomains was achieved, selectivity 
between CREBBP and EP300 bromodomains is yet 
to be described, and could prove far-fetched given the 
very high sequence identify and binding site similarity 
between these two domains (Figure 3A).
BRD7 & BRD9 bromodomains
The elusive biological functions of BRD7 and BRD9 
have motivated the development of selective chemical 
probes against the bromodomains of these proteins. 
The crystal structure of BRD9 revealed a different 
architecture of the ZA channel compared with BRD4-
BD1. This region is much larger in BRD9, with resi-
dues A162, F163, P164, T166 and I169 forming a large 
hydrophobic cavity. Additionally, the replacement of 
the so-called gatekeeper residue I146 in BRD4-BD1 
with Y222 in BRD9 results in blocking the access to 
the ‘GFF’ hydrophobic region that corresponds to the 
WPF shelf present in BET bromodomains, providing 
Figure 4. BRD9 bromodomain. (A) Superposition of the x-ray structure of BRD9 (in orange, PDB 4Z6I) and BRD4-BD1 (in gray, PDB 
3UVW). (B) x-ray structure of the ligands LP99 (PDB 4X6I), compound 28 (PDB 5E9V), I-BRD9 (PDB 4UIW) and BI-9564 (PDB 5F1H) 
bound to BRD9 (in orange).
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important structural differences that were deemed 
exploitable for ligand design (Figure 4A) [74].
Several BRD9 inhibitors have been reported. To 
date four distinct chemical series of compounds have 
been described that show selectivity toward BRD7 and 
BRD9 [75–79]. Starting from a verolactam fragment, 
Clark et al. aimed to extend interactions to the different 
hydrophobic regions between F160 and I169 of BRD9. 
This approach ultimately yielded LP99 (Figure 4B), a 
potent and selective inhibitor of BRD7 and BRD9, 
with a K
d
 against BRD9 and BRD7 of 99 and 909 
nM, respectively by ITC [75]. LP99 was broadly pro-
filed for selectivity by Differential Scanning Fluo-
rimetry (DSF) against all expressible bromodomains 
(48 of 61 in the human genome), showing <1°C sta-
bilization with other bromodomains [75]. Additionally, 
LP99 was found to be inactive versus 55 receptors and 
ion channels (CEREP panel) at 10 μM. The co-crystal 
structure of LP99 with BRD9 (PDB 4Z6I) confirmed 
that LP99 is stabilized by hydrophobic and aromatic 
residues in the KAc binding pocket and elucidated 
the structural basis for the stereospecific activity of 
(2R,3S)-LP99 (Figure 4B).
Another series of compounds that have shown selec-
tivity for BRD9 and BRD7 were designed based on 
the BAZ2A/BAZ2B inhibitor GSK2801 (discussed 
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later) [77,78]. The authors noted that the indolizine frag-
ment of GSK2801 had also affinity for BRD9. After 
optimization of the starting fragment, compound 28 
(from the original paper [77], Figure 4B) was found to be 
highly potent against BRD9 (K
d
 = 68 nM) and slightly 
less potent for BRD7 (K
d
 = 368 nM). The broader 
selectivity of this compound was assessed by DSF. 
Compound 28 is selective over most of the other bro-
modomain subfamilies, with modest affinity only for 
BRPF1B, CREBBP/p300 and FALZ. After determina-
tion of the x-ray structure of compound 28 bound to 
BRD9 (PDB 5E9V, Figure 4B), the selectivity observed 
could be rationalized by an interaction formed by 
the C-1 imidazopyridine moiety with the hydro-
phobic region sandwiched between I169 and F160, 
which is much narrower in the BET bromodomains 
(Figure 4B) [77].
The high similarity between BRD7 and BRD9 bro-
modomains (around 80% sequence homology; 36% 
in terms of overall residues) [76,77] makes the develop-
ment of a ligand selective only for one of these bromo-
domains a difficult task. However, this was achieved 
recently with the compound I-BRD9 (Figure 4B) [76]. 
I-BRD9 was identified through structure-based 
design, leading to greater than 700-fold selectivity over 
the BET subfamily members and 200-fold over the 
highly homologous BRD7 (K
d
 [BRD9, DiscoveRx] = 
1.9 nM, K
d
[BRD7, DiscoveRx] = 380 nM, K
d
[BRD4-
BD1, DiscoveRx] = 1400 nM) [76,79]. Several x-ray 
structures bound to BRD9 and BRD4-BD1 from 
several compounds during the extensive SAR process 
were solved in order to gain insights into the structural 
features that are responsible for the observed selectiv-
ity. Considering the basic nature of the amidine moi-
ety of I-BRD9 (Figure 4B), it was proposed that when 
charged it would sit more favorably in the less hydro-
phobic environment alongside A170 of BRD9 than 
beside L94 of BRD4-BD1 (Figure 4B, PDB 4UIW). 
The additional selectivity of I-BRD9 for BRD9 over 
BRD7 is, however, difficult to rationalize since only an 
NMR structure of BRD7 (PDB 2I7K) is reported to 
date [80]. Potential contributions to the observed selec-
tivity arise from differences in the constituent amino 
acids and in the architecture of the GFF region of 
BRD9 (G159 in BRD9 corresponds to A154 in BRD7) 
and the ZA loop (A162 in BRD9 corresponds to S157 
in BRD7) of these two bromodomains.
Very recently, two inhibitors of the BRD9 and BRD7 
bromodomains were developed using fragment-based 
screening and extensive structure-guided optimization 
by scientists at Boehringer Ingelheim in collaboration 
with SGC-Oxford and Cold Spring Harbor Labora-
tory (BI-7273 and BI-9564) [79]. The x-ray structure 
of BI-9564 bound to BRD9 (PDB 5F1H, Figure 4B) 
shows that the ligand makes water–bridged interac-
tions with the specific BRD9 gatekeeper residue Y222, 
while keeping a double hydrogen bond with N216 and 
a water-mediated hydrogen bond with Y173. The com-
pounds are potent (K
d
 in the 10-9–10-8 M range), highly 
selective (>1000-fold) against BRD4-BD1 and a panel 
of kinase and GPCR targets, have acceptable ADME 
and PK profiles, block AML cancer cell proliferation 
at ∼1 μM and display efficacious antitumor activity 
in a xenograft model of human AML [79], providing 
the most high-quality chemical probes for BRD7/9 
described to date.
Other inhibitors of BRD7/9 bromodomains have 
also been reported. These compounds either show 
mixed bromodomain pharmacology [44] or high affin-
ity toward members of the BET subfamily [81], which 
make them unsuitable as chemical probes. Interest-
ingly, the 9H-purine-based inhibitors described by 
Picaud et al. (Supplementary Figure 1) [81], although 
of modest selectivity, were able to induce an unprece-
dented rearrangement in the KAc recognition site (PDB 
4XY8), which was not observed in the crystal structure 
of the same compound bound to BRD4-BD1 (PDB 
4XY9). Specifically, the side chain of F77 (BRD9) 
rotated 120°, thus blocking the ZA-channel of the 
protein resulting in a steric clash around the ligands. 
These conformational changes could be exploited in 
principle to achieve selectivity for BRD7/9.
BAZ bromodomains
The BAZ subfamily of bromodomains (BAZ2A and 
BAZ2B) [82] had been considered one of the least drug-
gable in the human genome [51]. They are characterized 
by a shorter ZA loop, making the pocket fairly open 
and reducing its druggability, and by lack of the ZA 
channel. On the other hand, the residue correspond-
ing to M149 of BRD4-BD1 is much smaller in BAZ2B 
(A1953), and as a result cannot restrict the movement 
of the key Trp in the WPF shelf, potentially providing 
additional flexibility (Figure 5A).
In 2013, the first series of fragments with high 
micromolar affinity for the BAZ2B bromodomain 
were reported, which led to the structure-guided 
optimization of a γ-carboline-based inhibitor with 
single-digit micromolar affinity (PDB code of com-
pound 6: 4NRA, Figure 5B) [83]. Fragment screening 
was also pursued by GSK and led to the development 
of the first nanomolar affinity compound, GSK2801 
(Figure 5B), against the protein [78]. An indolizine frag-
ment containing an acyl group mimicking the KAc 
recognition interaction was grown and optimized 
into GSK2801 based on structural information. A co-
crystal structure (PDB 4RVR) showed that W1887 in 
BAZ2B is able to accommodate favorable π–stacking 
Figure 5. BAZ2B bromodomain. (A) Superposition of the x-ray structure of BAZ2B (in green, PDB 4NR9) and BRD4-BD1 (in gray, PDB 
3UVW). (B) x-ray structure of the compound 6 (PDB 4NRA), GSK2801 (PDB 4RVR) and BAZ2-ICR (PDB 4XUB) bound to BAZ2B.
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interactions with the inhibitor (Figure 5B). Bulky sub-
stituents in this part of the ligand introduced steric 
clashes against BET bromodomains, increasing selec-
tivity as a result. GSK2801 showed K
d
s of 140 and 
260 nM by ITC against BAZ2B and BAZ2A bro-
modomains, respectively. Only BRD9 and TAF1(L) 
bromodomains were detected as the major off-targets, 
after assessment of the GSK2801 selectivity for all 
human bromodomains by two orthogonal biophysical 
techniques, DSF and BLI.
In a parallel effort, Drouin et al. described BAZ2-
ICR (Figure 5B), an inhibitor that targets BAZ2A and 
BAZ2B in the nanomolar range achieving highly selec-
tive binding over the other bromodomains, except for 
CERC2, in a DSF screen [84]. BAZ2-ICR displayed no 
off-target activity at 10 μM concentration against a 
panel of 55 receptors and ion channels. The co-crystal 
structure (PDB 4XUB) provided one of the first exam-
ples of a pyrazole moiety acting as a KAc mimetic effi-
ciently filling out the binding pocket (Figure 5B) [84,85]. 
Noteworthy is the intramolecular π–stacking interac-
tions formed by the compound in its bound confor-
mation. This structural feature, often referred to as 
‘hydrophobic collapse’, could help to achieve potency 
against other less druggable bromodomains, since it 
can provide shape complementary and extensive con-
tacts in the case of more open and solvent-exposed 
binding sites, featuring less enclosed pockets, as is the 
case with BAZ2B.
BRPF bromodomains
The BRPF bromodomains KAc site closely resemble 
the BET and CREBBP bromodomains. This structural 
similarity translates in molecular recognition features, 
with identical fragments, for example, acetaminophen 
binding to BRPF bromodomains in a similar manner 
than for BET bromodomains and CREBBP [86]. One 
significant difference between BRD4 and BRPF1 is 
the hydrophobic ‘gatekeeper’ residue that forms one 
wall of the KAc site. This is I146 in BRD4-BD1 or 
Figure 6. BRPF inhibitors. Chemical structure representation of OF-1, PFI-4, IACS-9571, compound 34 and NI-57.
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V439 in BRD4-BD2 (Table 1). In contrast, a larger Phe 
residue occupies this position in the BRPF subfamily. 
This replacement promotes the selectivity seen in the 
1,3-dimethyl benzimidazolones-based series described 
by Demont et al. (Figure 6 & Figure 7A, PDB 4UYE). 
The best in class of this series, compound 3 (in the orig-
inal paper, Figure 7B) [48], showed a pIC
50
 for BRPF1 of 
7.1, while the pIC
50
 for BRD4 was 4.3 [48]. Selectivity 
for BRPF1 over BRPF2 and BRPF3 (pIC
50
of 5.1 and 
<4, respectively) could be achieved with compound 3, 
which was unexpected because the BRPF bromodo-
mains themselves are highly conserved and share >65% 
sequence identity. This observation could be rational-
ized by the substitution of S592 in BRPF2 or N619 in 
BRPF3 with P658 in BRPF1. Compound 3 was tested 
in the BROMOscan panel of 35 bromodomains and 
showed high selectivity over other bromodomains [48].
Keeping the 1,3-dimethyl benzimidazolone core, 
scientists at the SGC reported OF-1 and PFI-4 
(Figure 6). OF-1 (PDB 5FG4), developed in collabo-
ration with Pfizer, showed good affinity to all of the 
members of the BRPF subfamily. Selectivity against 
other bromodomains proved >100-fold overall but the 
closest off-target effects were found against BRD4 
(39-fold selectivity) and TIF1α (50% inhibition at 
20 μM in an alphascreen assay). PFI-4 (PDB 5FG5, 
Figure 6) binds to BRPF1B with a K
d
 of 13 nM by 
ITC [87]. Selectivity data have not been published yet 
for PFI-4.
With the initial aim to obtain selective TRIM24 
inhibitors, two molecules have been developed recently 
that are selective for BRPF and TRIM24, named 
IACS-9571 and compound 34 (Figure 6), respec-
tively [88,89]. Selectivity over BRD4 was ensured by the 
structural similarity of the starting fragments to the 
ones used to develop BRPF inhibitors [48], however, 
this meant that no selectivity for TRIM24 over BRPF 
bromodomains could be obtained. A trend was seen 
in both cases; in that introduction of bulky groups 
at the 6-para-methoxy position of the 1,3-dimethyl 
benzimidazolone core scaffold increased dramatically 
the affinity toward TRIM24, while maintaining high 
affinity for BRPF.
Only one nonrelated 1,3-dimethyl benzimidazolone 
compound has been disclosed that is able to bind in 
a selective manner the BRPF bromodomains. NI-57 
(Figure 6) [87] binds to the all BRPF subfamily mem-
bers in the nanomolar range [K
d
s measured by ITC 
are 31 nM (BRPF1B), 108 nM (BRPF2) and 408 nM 
(BRPF2)]. NI-57 is highly selective against other 
bromodomains, including the BETs, as measured by 
both biophysical and biochemical methods. The clos-
est off-target effect of NI-57 is against BRD9 (32-fold 
selective).
ATAD2 bromodomain
Similar to BAZ2B, ATAD2 has been considered a 
poorly druggable bromodomain since the KAc binding 
Figure 7. BRPF and ATAD2 bromodomains. (A) Superposition of the x-ray structures of compound 3 (in yellow) bound to BRPF1 (in 
purple, PDB 4UYE) and BRD4-BD1 (in gray, PDB 3UVW). (B) Superposition of the x-ray structures of compound 42 (in purple) bound to 
ATAD2 (in light pink, PDB 5A83) and BRD4-BD1 (in gray, PDB 3UVW).
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site is significantly divergent with respect to those of 
other druggable bromodomains [51]. Although ATAD2 
shares with most bromodomains the conserved residues 
responsible for KAc recognition, the KAc binding site 
is more open, polar and flexible than for example the 
one of BET bromodomains. When compared with 
BRD4-BD1, only three of seven residues lining the 
KAc binding pocket are shared, and the ZA loop is 
also two residues shorter than in BRD4. Additionally, 
W81 from the WPF is replaced by R1007, while M149 
is replaced by R1077. In ATAD2, the region corre-
sponding to the WPF shelf has been named ‘RVF shelf ’ 
(R1007-V1008-F1009) (Figure 7B). Several screening 
campaigns have been performed to find fragment-
size hits for ATAD2 [90,91], which yielded a number of 
weak-binding compounds. In parallel efforts, after a 
long and careful structure-based optimization a group 
at GSK developed potent and selective naphthyridone-
based ATAD2 inhibitors [92,93]. In a first step, the 
authors were able to find low micromolar inhibitors for 
ATAD2 that, however, did not exhibit selectivity over 
BRD4 [93]. Subsequently, strategies to increase affinity 
and selectivity over BRD4-BD1 were explored. First, 
complementarity with the RVF shelf was optimized 
with appropriate polar substitutions in the compounds. 
Second, additional interactions with the backbone NH 
group of D1014 in the ZA loop were introduced, yield-
ing the best compound of this series, compound 38 (in 
the original paper, Supplementary Figure 1) [92], with 
double-digit nanomolar binding affinities for ATAD2 
(pIC
50
ATAD2 = 6.9 by TR-FRET) and showing 
>100-fold selectivity over the BET bromodomains. 
The x-ray structure of a close derivative, compound 
42, bound to ATAD2 bromodomain was elucidated 
(PDB code of compound 42: 5A83, Figure 7B). How-
ever, the high potency and selectivity of compound 38 
came at the expense of greater hydrophilicity that was 
solved in part with compound 46 (pIC
50
ATAD2 = 6.5 
by TR-FRET, Supplementary Figure 1). Selectivity 
of compound 46 over the BET bromodomains was 
confirmed by Bromoscan with a window of at least 
>400-fold (pKi by BROMOscan 7.7 against ATAD2 
and 5.1 against BRD4-BD1). For the other bromodo-
mains tested, the highest activity was with the second 
bromodomains of TAF1 and TAF1L (pKi 7.3 and 6.9, 
respectively, by BROMOscan). In addition, chemopro-
teomics pulldown experiments were performed and K
d
s 
for the off-target bromodomains were determined [92].
Other bromodomains
Few other bromodomains have been selectively tar-
geted until today. Following a new 19F-NMR dual 
screening method using fluorinated tryptophan 
resonances on two bromodomain-containing pro-
teins, Urick et al. discovered the first selective BPTF 
inhibitor, called AU1 (Supplementary Figure 1), from a 
library of 229 selected small molecules screened against 
BRD4-BD1 and BPTF [94]. SGC and Pfizer have col-
laborated to develop PFI-3 (Supplementary Figure 1, 
PDB 5DKC [SMARCA2] and 5DKD [SMARCA4]), 
a selective chemical probe for SMARCA 2/4 (89 nM 
for SMARCA4 by ITC) and PB1(5) (48 nM by ITC) 
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bromodomains [95]. No interaction was observed with 
other bromodomains by DSF, and there was no cross-
reactivity in a kinase panel of 36 kinases [95]. Despite 
the achieved potency and pan-selectivity, target bro-
modomain inhibition by PFI-3 did not impart the 
expected antiproliferative phenotype in relevant cancer 
cell lines, in contrast to what was observed with target 
knockdown by RNAi [95]. In another collaborative proj-
ect, SGC and Novartis disclosed the selective CECR2 
inhibitor NVS-CERC2-1 (Supplementary Figure 1) [87]. 
With an affinity of two-digit nanomolar and no inter-
action with the rest of the bromodomains in a BRD 
panel (48 targets), NVS-CERC2-1 is the only exam-
ple to date of a chemical probe for this subfamily of 
bromodomains.
Selectivity within BET bromodomains: BD1 
versus BD2
All BET proteins are characterized by two N-terminal 
tandem domains (BD1 and BD2) followed by an extra 
terminal domain (ET domain). While BD1s and BD2s 
separately share greater than 75% sequence identity 
among themselves, only 38% cross-domain sequence 
identity is observed, suggesting distinct evolutionary 
ancestors and distinct functions [96]. However, all the 
BET bromodomains exhibit 95% sequence identity 
at the KAc binding pocket [97]. Sequence compari-
son between the two bromodomains of BRD4 in the 
proximity of the KAc peptide-binding site (Figure 8A & 
Table 1) shows three crucial residue positions that differ:
•	 Q85 in BD1 is a Lys residue in BD2 (K378); 
•	 D144 in the BC loop of BD1 is a His residue in 
BD2 (H437); and 
•	 I146 is a Val in BD2 (V439).
 Although BET BD1 and BD2 show a high sequence 
similarity in the substrate-binding site, they exhibit 
different patterns of recognition of acetylated histone 
peptide target sequences [24]. A single BD1 or BD2 of 
BRD4 is individually able to interact with acetylated 
H4 peptide, however, only BD1 was found to recog-
nize specifically N-terminal acetylated H4 peptides 
in a sequence-dependent manner, while BD2s were 
found to be more promiscuous [24]. As a general fea-
ture, BD1s of BET proteins appear to have a role in 
specifically recognizing H4 acetylation marks, whereas 
BD2s could have broader specificity toward acetylated 
substrates. The presence of two additional conserved 
regions, one containing the N-terminal cluster of casein 
kinase II phosphorylation sites (NPS) and one contain-
ing residues-enriched interaction domain (BID) situ-
ated downstream of BD2 in all BET proteins, would 
suggest that BD1 and BD2 may be differentially 
regulated by post-translational modification [98].
Several studies have shown that each BET bromodo-
main has a distinct function in the regulation of ordered 
gene transcription in chromatin possibly consequent to 
the interaction with lysine-acetylated histones or with 
other partner proteins. Gamsjaeger et al. showed that 
the two acetylated lysines in a sequence adjacent to the 
DNA-binding domain of the hematopoietic transcrip-
tion factor GATA 1 are only recognized by the BD1 
bromodomain of BRD3, while BD2 does not play 
any significant role in the recognition [37,99]. Shi et al. 
showed that Twist (an EMT-activating transcriptional 
factor) acetylated peptides could bind BRD4-BD2 with 
selectivity of >4-fold over BRD4-BD1 in a fluorescence 
polarization assay, suggesting that Twist preferentially 
interacts with the second bromodomain [100]. The pref-
erential selectivity of the diacetylated Twist toward 
BD2 was attributed to a charged amino acid residue 
(D144 in BD1 or H437 in BD2) surrounding the 
KAc-binding pocket of BDs, together with additional 
residues beyond the diacetylation motif [100].
The same structural difference (D144 in BD1 or H437 
in BD2) was highlighted as potentially playing a role in 
the observed selectivity of a compound called olinone for 
BRD4-BD1 over BD2 [97]. Olinone (Figure 8B) is a selec-
tive small-molecule inhibitor of the first bromodomain 
of BET proteins, consistently exhibiting over 100-fold 
higher binding affinity to BD1 (K
d
 = 3.4 μM) than BD2 
(no detectable binding) by ITC for all of the BET bro-
modomains. A tetrahydropyrido indole chemical frag-
ment (MS7972, Supplementary Figure 1) was identified 
as a hit from an NMR-based screen and showed modest 
activity as inhibitor of the CREBBP bromodomain [65]. 
Using MS7972 as a starting point, the authors incor-
porated longer acetamidoalkyl group substituents at the 
N-indole core, mimicking the natural KAc substrate. 
The x-ray structure of the BRD4-BD1/olinone complex 
(PDB 4QB3, Figure 8B) revealed that the alkyl group 
containing four methylene units adopts identical con-
formation and position as that of the acetylated-K5 
side chain of the histone H4K5ac/K8ac peptide when 
bound to BRD4-BD1. Crucial for the BD1 selectivity, 
the modified triheterocyclic moiety containing a cyclic 
amide packs against the side chains of W81 and P82 and 
directly interacts with the specific BD1 residue D144 at 
the opening of the KAc binding pocket formed between 
the ZA and BC loops. In contrast, the corresponding 
residue in BD2, H437, would be predicted to clash with 
the cyclic moiety of olinone (Figure 8A).
The ability of olinone to bind preferentially the first 
bromodomain of BET proteins increases its potential 
to be used as a chemical probe to address how each of 
Figure 8. Selectivity between BD1 and BD2 BET bromodomains. (A) Superposition of the x-ray structure of  
BRD4-BD1 (in yellow, PDB 4QB3) and BRD2-BD2 (in blue, PDB 4J1P). (B) x-ray structure of olinone bound to the 
BRD4-BD1 (in yellow, PDB 4QB3). (C) x-ray structure of RVX-208 bound to the BRD2-BD2 (in yellow, PDB 4J1P).
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the paired bromodomains of BET proteins may func-
tion individually in the control of gene transcription in 
chromatin. In fact, comparison of the effect between 
olinone with MS417 (Supplementary Figure 1) that is 
equally potent against BD1 and BD2 showed dramatic 
differences in the biological response of oligodendro-
cyte progenitor lineage cells to compound treatments: 
whereas olinone promoted differentiation, MS417 
inhibited it [97]. While these observations were interest-
ing and potentially pointing to different roles for BD1 
versus BD2, this was not conclusive due to the low 
potency of olinone and potential off-targets mediating 
its biological activity.
Preferential binding for BD1 over BD2 has been 
achieved with another class of diazobenzene-based 
BET inhibitors [101]. MS436 (Supplementary Figure 1), 
with an estimated K i of 30–50 nM for BRD4-BD1, 
and 10-fold selectivity over BD2, was the best inhibitor 
obtained after extensive lead optimization [101]. MS611 
(Supplementary Figure 1) is another diazobenzene-
based BET inhibitor with selectivity for BD1 against 
BD2 more recently described by the same group [97]. 
Surprisingly, MS611 showed 100-fold selectivity only 
for the BDs of the BRD4 bromodomain (K i = 0.41 μM 
[BRD4-BD1]; 41.3 μM [BRD4-BD2]), while no 
or very small differences in affinity were observed 
between the two BDs of BRD2 and BRD3. Further 
structural analysis is warranted to elucidate the basis 
of these remarkable differences observed between BET 
bromodomains.
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While olinone represents the first selective BD1 
inhibitor, RVX-208 (Figure 1 & Figure 8C) was the 
first BD2 selective inhibitor reported. RVX-208 (also 
named RVX000222 and apabetalone) was developed 
by Resverlogix Corp. and is now in clinical Phase III 
for the treatment of cardiovascular diseases associated 
with atherosclerosis and diabetes. RVX-208 is a small 
molecule that binds to BET bromodomains and com-
petes for acetylated histone H4 peptide with a high 
preference for BD2 over BD1. Two papers published 
around the same time described the biophysical and 
structural characterization of this small molecule 
against BET bromodomains [102,103]. Although the 
results are very consistent along the two papers, some 
discrepancies about the absolute binding affinities mea-
sured by ITC of RVX-208 against BD1 and BD2 are 
seen. While Picaud et al. measured 23-fold selectivity 
for BRD2 [K
d
 = 5790 nM (BD1) and 251 nM (BD2)] 
and eightfold selectivity for BRD4 [K
d
 = 1142 nM 
(BD1) and 135 nM (BD2), McLure et al. measured 
82-fold selectivity for BRD2 [K
d
 = 16900 nM (BD1) 
and 206 nM (BD2)] and 30-fold selectivity for BRD4 
[K
d
 = 8930 nM (BD1) and 303 nM (BD2)]. These 
differences may reflect different conditions used in the 
experiments.
The high-resolution crystal structure of RVX-208 
bound to BRD4-BD1 (PDB 4J3I and 4MR4) 
and BRD2-BD2 (PDB 4J1P and 4MR6) were 
resolved [102,103]. RVX-208 binds to the KAc pocket 
in a peptide-competitive manner, but unlike (+)-JQ1 
it does not occupy the WPF region (Figure 8C). In all 
crystal structures, RVX-208 adopts a conserved bind-
ing mode. The carbonyl oxygen and the nitrogen 
atoms of the quinazoline ring system act as the KAc 
mimetic moiety, forming a hydrogen bond with the 
conserved N429 (BRD2-BD2) and a water-mediated 
hydrogen bond with Y386. The BD2 unique residue 
H433 in BRD2 flips into the KAc binding site pack-
ing against the phenyl ring of RVX-208, providing a 
possible explanation for the tighter affinity for BD2s 
(Figure 8C). Moreover, RVX-208 makes no direct 
interactions with residues unique to BD1, except to 
a water-mediated hydrogen bond with Q85 (K378 in 
BRD2-BD2).
Selectivity for the second over the first BET bro-
modomain using the IBET/(+)-JQ1 triazolodiaz-
epine scaffold was observed by Baud et al. in the 
context of a bump-and-hole approach (see ‘Chemical 
biology & chemical genetics approaches to exploit 
selectivity’ section of this review) [104]. An analog 
of I-BET762/(+)-JQ1 (compound 28 in the origi-
nal paper [104], Supplementary Figure 1) in which an 
indole group replaces the p-chlorophenyl group of 
I-BET762/(+)-JQ1 displayed a marked BD2 selectivity 
profile (20-fold). The observed selectivity was rational-
ized by observing in the co-crystal structures two dis-
tinct conformations (open and closed) for the His side 
chain (H433 in BRD2-BD2). The newly introduced 
indole group of the ligand exploits the closed confor-
mation of H433 by forming an edge-to-face π-stack 
that would not be possible with the BD1 Asp residue 
(PDB 5DFD). These results indicate that BD2 ver-
sus BD1 isoform selectivity could be optimized with 
the aryl triazolodiazepine scaffold via comprehensive 
substitution of the parent p-chlorophenyl ring [104].
Finally, several compounds developed by Zenith 
Epigenetics (structure undisclosed) have also shown a 
remarkable selectivity for BRD4-BD2 toward BRD4-
BD1. The best-in-class compound, ZEN297, showed 
a 60-fold selectivity (IC
50
 BRD4-BD1 = 1.2 μM; IC
50
 
BRD4-BD2 = 0.02 μM) [105]. Despite their potential 
as chemical probes to elucidate the roles of the sec-
ond bromodomains in BET proteins biology, the low 
potency of BD2-selective compounds for inhibiting 
tumor cell proliferation and c-MYC expression render 
them less attractive drug leads than BET inhibitors 
with BD1 activity.
Selectivity within the BET subfamily
The development of an inhibitor selective for one of 
the bromodomain protein inside the BET subfam-
ily has originated a tremendous interest in the aca-
demic and industrial settings. Although dozens of 
new molecular entities have been published and dis-
closed in the last 5 years, none of these have exhib-
ited exquisite selectivity for a single BET protein over 
the others, and little is known about how to achieve 
this challenging selectivity. This is in part as a result 
of the high sequence identity within the KAc bind-
ing pocket of BET bromodomains (Table 1). How-
ever, very recently, Raux et al. indicated a different 
dynamic behavior of the ZA loop between the differ-
ent BET bromodomains that could be exploited to 
fine tune selectivity [106]. In this work, a new class of 
xanthine-based inhibitors (Supplementary Figure 1) 
discovered using a ‘protein–protein interaction inhi-
bition (2P2I)-oriented’ collection of compounds 
was able to yield the first described low micromo-
lar selective inhibitor targeting BRD4-BD1 with a 
greater than tenfold ratio in binding affinity toward 
any other BET bromodomain. A potential hydro-
gen bond between the triazolo fragment of the new 
xanthine series and the BET conserved D88 residue 
that could be more stabilized in the case of BRD4-
BD1, could in part explain the observed selective 
profiles. Additionally, van der Waals interaction with 
the side chain of the aforementioned Q85 in BRD4-
BD1 (K378 in BRDs-BD2) contributed toward 
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the preferential binding observed toward the BD1 
bromodomain.
The pharmaceutical company Bayer disclosed in 
The Annual Meeting of The American Association 
for Cancer Research in 2015 the biochemical char-
acteristics of BAY1238097 [107]. This compound, 
based on a novel scaffold (structure undisclosed), 
showed IC
50
 values of 63 nM for BRD4, 609 nM 
for BRD3 and 2430 nM for BRD2, corresponding 
to a selectivity of up to 39-fold for BRD4 versus 
BRD2. Chromatin immunoprecipitation (ChIP) 
experiments performed in MOLM-13 (AML) and 
MOLP-8 (MM) cell lines additionally revealed that 
BAY1238097 prevented binding of BRD4 to c-Myc 
regulatory region.
Another compound showing a degree of intra-BET 
selectivity in vivo is OTX015 (Figure 1), a BET inhibi-
tor in clinical Phase III, which binds BET proteins 
with IC
50
 around 100 nM [108]. Coude et al. showed 
that OTX015 exposure decreased the expression of 
BRD2 and BRD4 and c-MYC, while BRD3 expres-
sion remained unaffected, in a broad range of acute 
leukemia cell lines and patient-derived leukemic 
samples [108].
Chemical biology & chemical genetics 
approaches to exploit selectivity
Bump-&-hole approach
The difficulty to obtain highly selective inhibitors for 
single BET bromodomains has motivated chemical 
biology/genetic approaches to address the challenges. 
Previous work on different enzymes, including protein 
kinases [109,110] provided proof-of-concept for generat-
ing allele-specific cofactors and inhibitors using a so-
called ‘bump-and-hole’ approach. Using site-directed 
mutagenesis a ‘hole’ is introduced in the protein by 
replacing a natural amino acid with a smaller one, and 
this is compensated by introducing a bulky hydro-
phobic ‘bump’ into the natural ligand. This would 
be expected to confer high selectivity for the intro-
duced mutant over the wild-type protein as the latter 
should not bind the ‘bumped’ ligand owing to steric 
hindrance.
Baud et al. successfully developed this approach 
to achieve exquisite single target selectivity of BET 
bromodomain chemical probes [111]. After sequence 
alignments and structural analysis guided by molecu-
lar docking, the authors identified a residue from the 
ZA-loop (L383 in BRD2-BD2) that is strictly con-
Table 1. Sequence similarity between residues of the KAc binding sites of BRD2-BD1, BRD3-BD1, 
BRD4-BD1 and BRD4-BD2.
Motifs BRD2-BD1 BRD3-BD1 BRD4-BD1 BRD4-BD2
Conserved Asn N156 N116 N140 N433
Conserved Tyr Y113 Y73 Y97 Y432
WPF motif W97 W57 W81 W374
WPF motif P98 P58 P82 P375
WPF motif F99 F59 F83 F376
ZA loop D104 D64 D88 D381
ZA loop A105 A65 A89 V382† 
ZA loop V106† I66† V90† E383†
ZA loop K107 K67 K91 A384†
ZA loop L108 L68 L92 L385
ZA loop G109† N69† N93† G386†
ZA loop L110 L70 L94 L387
ZA channel R100† Y60 Q84† Y377
ZA channel Q101 Q61 Q85 K378†
ZA channel P102 P62 P86 P379
ZA channel V103 V63 V87 V380
Gatekeeper I162 I122 I146 V439†
BC loop T159 T119 G143† D436†
BC loop D160 D120 D144 H437†
BC loop D161 D121 D145 E438†
†The residues that differ between the BET bromodomains and can be exploited to achieve selectivity.
Figure 9. Bump-and-hole approach. Superposition of the x-ray structure of the ET (in cyan) bound to the  
BRD2-BD2 L383A (in gray, PDB 4QEW) and parent ligand I-BET762 (in orange) bound to the BRD2-BD2 (not showed, 
PDB 5DFC).
I-BET762
(GSK-525762)
NN
O NH
NN
ClO
NN
O O
NN
ET
ClO
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served within BET bromodomains. Mutation of this 
into a smaller amino acid (Ala) created a ‘hole’ that did 
not significantly affect BET bromodomain stability 
and structural integrity, leading to mutant BET pro-
teins of reasonable functionality that could accommo-
date a modified inhibitor. An ethylated derivate (named 
ET, Figure 9) of a methylester analog of I-BET762 
was designed and found to bind to all mutant BET 
bromodomains with nanomolar affinities, while only 
binding the wild-type versions with single- to double-
digit micromolar affinities. ET achieved up to 540-fold 
selectivity and no less than 30-fold (average 160-fold) 
across the entire BET subfamily, and high selectivity 
was retained within tandem constructs. To validate 
this strategy, x-ray structures of BRD2-BD2
L383A
 in 
complex with the methylated and ethylated bumped 
ligands were solved (PDB 4QEV and 4QEW respec-
tively), showing that they adopt the same bind-
ing mode as I-BET762 and (+)-JQ1, positioning the 
respective methyl and ethyl substituents toward the 
hole introduced by the mutation (Figure 9). They went 
on and applied the approach in cells to demonstrate 
that selective pharmacological blockade of the first 
bromodomain of BRD4 is sufficient to displace the 
protein from chromatin, consistent with chromatin 
binding of BRD4 being principally influenced by BD1 
over BD2 [111]. This study represents the first devel-
opment of an allele-selective bump-and-hole approach 
against a protein–protein interaction target.
The same group attempted to exploit mutations in 
other conserved residues around the KAc binding site 
(V376A, W370F, W370H in BRD2-BD2) [104]. How-
ever, these new mutations did not lead to the desired 
increase in binding selectivity for mutant versus 
wild-type when targeted with appropriately designed 
bumped (+)-JQ1/I-BET762 analogs.
PROTAC approach
With the aim to yield new chemical tools for studying 
BET bromodomain protein, Zengerle et al. described 
a new series of PROTACs (Proteolysis Targeting Chi-
mera) molecules to trigger the intracellular destruction 
of BET proteins [112]. PROTACs are hetero−bifunc-
tional small molecules that allow selective recruitment 
of a protein of interest to the ubiquitin-proteasome pro-
teolytic machinery. By linking an optimized drug-like 
ligand able to bind to the von Hippel-Lindau E3 ligase 
protein to the BET bromodomain inhibitor (+)-JQ1, 
researchers at the University of Dundee were able to 
achieve rapid, effective and prolonged degradation of 
BET bromodomains with small molecules. Unexpect-
edly, the most potent novel PROTAC inhibitor, MZ1 
(Supplementary Figure 1), showed a preferential deg-
radation effect on BRD4 over the highly homologous 
BRD2 and BRD3 at relatively low concentrations. This 
selectivity window translated in a more BRD4-specific 
downstream transcriptional response in cancer cells 
treated with MZ1 as compared with treatment with 
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(+)-JQ1 [112]. The VHL-targeting BET PROTACs 
reported in this study demonstrate for the first time 
the possibility for turning unselective or pan-selective 
inhibitors into chemical degraders of enhanced tar-
get selectivity profile. The authors speculated that the 
observed target selectivity could arise from preferential 
recruitment of BRD4 relative to BRD2/3 by MZ1 in a 
ternary complex with the VHL E3 ligase, or more effi-
cient downstream polyubiquination of lysine residues 
on the surface of BRD4, which warrant further struc-
tural and mechanistic studies. Overall, MZ1 showed 
improvements over (+)-JQ1 as a chemical probe due 
to its more limited transcriptional response and as a 
potential molecular therapeutic, providing unique 
opportunity to validate the therapeutic benefit of selec-
tive BRD4 removal, for example, compared with or in 
addition to pan-selective BET inhibition.
A similar approach to degrade BET bromodo-
mains with a PROTAC molecule was pursued by 
Lu et al. [113]. In this case, OTX015 was used as the 
BET bromodomain binding ligand, which was joined 
to a phtalimide binding ligand for the E3 ligase 
cereblon. Cereblon-targeting BET PROTAC ARV-825 
(Supplementary Figure 1) induced effective degradation 
of all BET proteins and a strikingly more pronounced 
anti-proliferative and c-MYC suppressive effect com-
pared with (+)-JQ1 and OTX015 alone [113,114]. Inter-
estingly, no target degradation selectivity between 
BRD2, BRD3 and BRD4 was observed. A similar 
PROTAC strategy was followed by Winter et al. where 
(+)-JQ1 was conjugated to the same phtalimide ligand 
for cereblon, which induced cereblon-dependent BET 
protein degradation in cells and in vivo and delayed 
leukemia progression in mice [115]. Although the new 
compound dBET1 (Supplementary Figure 1) showed 
pan-selectivity for inducing degradation of BET 
proteins, no noteworthy intra-BET selectivity was 
observed [115].
Chem-Seq approach
The ability to map direct interactions of molecules 
with chromatin genome-wide could provide important 
information on the on-target effect of small molecules, 
aiding biological insights. Anders et al. used Chem-seq, 
a method based on chemical affinity capture and par-
allel unbiased DNA sequencing, to investigate the 
genome-wide binding of the bromodomain inhibitor 
(+)-JQ1 to the BRD2, BRD3 and BRD4 in multiple 
myeloma cells (MM1.S) [116]. The authors showed that 
the genomic sites bound by a biotinylated derivate of 
(+)-JQ1 (bio-JQ1, Supplementary Figure 1) are highly 
similar to the sites occupied by the native BRD2, 
BRD3 and BRD4 proteins. However, inspection 
of gene tracks for regions differentially occupied by 
bio-JQ1 provided evidence that bio-JQ1 tends to co-
occupy enhancers where there are substantial BRD4 
signals, and lower signals for BRD2 and BRD3. These 
results indicated that the pattern of (+)-JQ1 occupancy 
of chromatin is most strongly correlated with that of 
BRD4 in MM1.S cells [116].
Off-target effects
Dual bromodomain/kinase inhibitors
The target selectivity and potential off-target effects 
of kinase inhibitors remain an important issue in their 
utilization as kinase chemical probes [117]. Several 
recent studies have revealed interesting off-target bind-
ing of BET bromodomains by diverse kinase inhibitors.
Intrigued by the observation that BRD4 exerts 
kinase activity against Pol II [118], Martin et al. decided 
to elucidate the x-ray structure of the potent CDK 
inhibitor dinaciclib with the BET bromodomain 
BRDT-BD1 (PDB 4KCX, Figure 10) [119]. Surprisingly, 
the structure revealed that dinaciclib binds exactly to 
the KAc binding site of BRDT, albeit with a differ-
ent binding mode than (+)-JQ1, resulting in a subop-
timal binding affinity compared with (+)-JQ1 (K
d
 for 
BRDT-BD1 of 37 μM in qPCR-based assay). The pyr-
idine oxide moiety of dinaciclib acts as a KAc mimetic 
interacting with the crucial Asn amino acid (N109 
in BRDT-BD1) and the pyrazolo-pyrimidine moi-
ety lies parallel to the WPF shelf, making additional 
water-mediated hydrogen bond with the backbone 
of ZA channel residues P55 and V56. An additional 
profiling of dinaciclib against a panel of 24 bromodo-
mains revealed that apart from BET bromodomains, 
the only other bromodomains with binding potential 
for dinaciclib were TAF1 and TAF1L. These findings 
were consistent with the hypothesis that BET proteins 
could be potential off-targets of ATP-site-directed 
kinase inhibitors. Because of the potential of synergis-
tic pharmacology between kinase and BET inhibition 
in cancer cell lines, several kinase inhibitors have since 
been investigated for their potential to bind to BET 
bromodomains [49,120,121].
Through a robotic co-crystallization screening 
campaign Ember et al. demonstrated that a number 
of protein kinase inhibitors currently in the clinic, 
for example, BI-2536 (Supplementary Figure 1) and 
TG-101348 (Supplementary Figure 1), a PLK1 and a 
JAK2-FLT3 kinase inhibitor, respectively, also bind to 
members of the bromodomain family with a potency 
and selectivity that would be predicted to be therapeu-
tically relevant [49]. A total of 14 kinase inhibitors were 
characterized by Ember et al. as BRD4-BD1 inhibi-
tors, the majority of them showing micromolar inhibi-
tion of BET proteins. x-ray cocrystal structures showed 
that most of the kinase inhibitors take a slightly differ-
Figure 10. Dual bromodomain/kinase inhibitors. x-ray structure of the dinaciclib (in magenta) bound to the 
BRDT-BD1 BET bromodomain (in green, PDB 4KCX)
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ent conformation when they bind to the bromodomain 
compared with when they bind to the ATP site of the 
kinase, which may result in unfavorably high energy 
states, and consequently, reduced binding potential 
toward BET bromodomains. Importantly, none of 
the kinase inhibitors investigated in the paper inter-
act with the characteristic water network of the KAc 
binding site, opening opportunities for the develop-
ment of a novel class of BET bromodomains, directly 
interacting with the residues of the binding site. In 
parallel, Dittman et al. following a quantitative che-
moproteomic approach demostrated that LY294002 
(Supplementary Figure 1) and its negative control ana-
log LY303511 (Supplementary Figure 1), two inhibitors 
of PI3K enzymes, were both able to block the first, but 
not the second, bromodomain of BRD2, BRD3 and 
BRD4 [120]. Further, it was found that the cellular and 
transcriptional effects of LY303511 were accounted 
for largely by their off-target interaction with BET 
bromodomains.
In a separate study, Ciceri et al. also reported that 
several clinical kinase inhibitors, such as BI-2536 and 
TG-101348 (Supplementary Figure 1) inhibit bromo-
domains with therapeutically relevant potencies [122]. 
In fact, PLK1 and its inhibitor BI-2536 has been the 
focus of some of the efforts to develop dual inhibi-
tors [123]. These combination of activities on indepen-
dent oncogenic pathways exemplify a new strategy 
for rational single-agent poly-pharmacological target-
ing and provide a new structural framework for the 
rational design of next-generation BET-selective and 
dual-activity BET-kinase inhibitors.
GABA inhibitors
For many years, the benzodiazepine chemical group 
has been considered as a ‘privileged scaffold’ in drug 
discovery [104,124,125]. A large number of approved 
inhibitors of the GABA receptors contain the benzo-
diazepine moiety. In addition, several bromodomain 
inhibitors in clinical trials such as I-BET762, (+)-JQ1 
and OTX15 (Figure 1) also have a benzodiazepine-based 
structure.
Filippakopoulos et al. provided insights into the 
structure–activity relationships and selectivity of the 
approved GABA inhibitors toward the BET bromo-
domains [126]. They found that alprazolam (Figure 11) 
binds with low micromolar affinity to BRD4-BD1. 
The co-crystal structure of alprazolam with BRD4-
BD1 showed that the triazolo ring of alprazolam 
forms a hydrogen bond with the conserved Asn resi-
due. Unexpectedly, also midazolam interacts with 
BET bromodomains, preferentially with BD2, in the 
micromolar range of affinity. Co-crystal structure of 
midazolam with BRD4-BD1 shows that although 
midazolam lacks the hydrogen bond forming nitrogen 
in the triazolo group, it is able to bind to this BET 
bromodomain after a reorganization of the network of 
conserved water molecules inside of the KAc binding 
site [126]. However, the micromolar affinities of these 
compounds make unlikely that this activity will cause 
side effects due to inhibition of BET bromodomains.
Conclusion & future perspective
Epigenetic control of gene expression plays a signifi-
cant role in a variety of diseases, including cancer and 
Figure 11. GABA inhibitors. Chemical structure 
representation of alprazolam and midazolam.
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inflammation. Protein readers of histone acetylation 
and their bromodomains have emerged as attractive 
drug targets for these diseases, yet little is known about 
their individual biological function, how they work 
inside cells in both physiological and pathophysiologi-
cal contexts, and how they should be best modulated 
pharmacologically. For these reasons, much interest 
has spurred in epigenetic medicinal chemistry and 
drug discovery, and specifically in the structure-guided 
development of chemical probes for bromodomains, 
to help fill these knowledge gaps and validate new 
potential drug targets.
In this review, we have highlighted the state-of-
the-art in the field, focusing on the in vitro on-target 
selectivity of the probes reported to date, as measured 
using biophysical techniques mostly against puri-
fied proteins. Robust in vitro selectivity profiling of 
chemical probes is advocated, using appropriate assays 
such as the BromoScan assay provided by DiscoveRx 
and related assays over less quantitative methods, for 
example, DSF, as well as selectivity profiling against 
key target classes, for example, kinases and GPCRs. 
We expect efforts in future to focus on assessment of 
target engagement selectivity inside cells in an unbi-
ased fashion. Progress in this direction will likely take 
advantage of new developments in molecular biology 
and genome editing, for example, by clustered regu-
larly interspaced short palindromic repeats (CRISPR)-
Cas9 [127], and the translation of biophysical measure-
ments directly in cellular environment, as exemplified 
by cellular thermal shift assay (CETSA) [128], cellular 
thermal profiling by mass spectrometry [129] and meth-
ods using bioluminescence resonance energy transfer 
(BRET) such as NanoBRET assay [130,131].
The cutting-edge progress achieved in recent years 
in the field by both industrial and academic scien-
tists demonstrates that it is possible to obtain some 
degree of target selectivity within selected bromo-
domain subfamilies. For chemical probes targeting 
non-BET family members, selectivity against BET 
bromodomains, particularly BRD4-BD1, is consid-
ered a critical requirement to eliminate any unwanted 
BRD4-dependent cellular effect. It has nevertheless 
remained a challenge to achieve intra-family single 
target selectivity. When this cannot be achieved 
by targeting the KAc pocket, alternative protein 
domains or more specific PPI binding sites outside 
the KAc pocket will likely need to be explored. It is 
also envisaged that covalent reversible or irreversible 
inhibition, which has so far not been much exploited 
against bromodomains, could help to enhance 
on-target selectivity.
In addition to conventional inhibitors, more 
sophisticated chemical biology approaches such as 
bump-and-hole and PROTACs have demonstrated 
that they can lead to single-target selectivity even when 
starting from the pan-selective inhibitor (+)-JQ1. Such 
new, more refined chemical tools are poised for many 
applications in the near future to dissect individual 
physiological roles of BET proteins in vivo, and could 
be widely extended to other BCPs as well as other 
epigenetic reader domains.
Despite the extraordinary progress to date, there 
still remain many challenges facing the field ahead. 
Bromodomains have proven to be highly ‘ligandable’ 
targets, especially for small-molecule fragments, and 
to be particularly suitable to biophysical fragment 
screening. The readiness with which nanomolar bind-
ing affinities can be achieved for a given bromodomain 
seems to be dependent on the nature of each target, yet 
inhibitor potency can be achieved with most bromo-
domains. From a drug discovery perspective, modula-
tion of BET proteins with bromodomain inhibitors is 
now a validated therapeutic approach. It remains to be 
seen to what extent the many inhibitors for non-BET 
bromodomains that are available and will continue to 
emerge can exert a desired level of cellular efficacy, and 
consequently the question of which target will prove 
to be ‘druggable’ as well as ‘ligandable’ remains open. 
Validated drug targets will likely be determined more 
by the biology of individual BCPs, than by the ligand-
ability of their bromodomain. Effective coupling of 
chemical with biological target validation approaches, 
surmounting inherent challenges associated with the 
complexity of many BCPs and their function, will be 
paramount to ensure the most relevant targets are pri-
oritized in future. Nevertheless, we predict that new 
small molecule probes will continue to be developed 
in this area, providing yet more tools for the scientific 
community to use to help answer important biological 
questions.
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Executive summary
•	 With the publication in 2010 of BET inhibitors (+)-JQ1 and I-BET762, there has been an explosion of small 
molecules discovered or designed to target bromodomains in the human family.
•	 The high similarity within the different subfamilies of bromodomains, in particular at the level of their 
KAc binding sites, poses inherent challenges to the development of selective bromodomain inhibitors for 
delivering high-quality chemical probes.
•	 Despite achieving several compounds in clinical trials, the development of BET inhibitors as chemical probes of 
individual BET proteins has remained a major challenge, due to the lack of single target selectivity.
•	 We exemplify the efforts to obtain selective bromodomains-class inhibitors with case studies taken not only 
from the BET subfamily but also from bromodomain targets in other subfamilies.
•	 The ability of BET inhibitors to bind preferentially BD1 or BD2 of BET proteins increases their potential to be 
used as a chemical probe to address how each of the paired bromodomains of BET proteins may function 
individually in the control of gene transcription in chromatin.
•	 Innovative chemical biology and chemical genetic approaches such as bump-and-hole, PROTACs and 
Chem-Seq approaches allow to address and enhance on-target selectivity and efficacy, and interrogate 
context-dependent mode of action of BET inhibitors.
•	 Several studies have revealed interesting and unexpected off-target binding of BET bromodomains by 
inhibitors previously developed against other targets, such as protein kinases and receptors.
•	 We have described key challenges facing the development of bromodomain inhibitors as highly selective 
chemical probes, of the quality necessary for use as tools to address biological questions.
•	 Future efforts to attempt to solve these challenges should focus on development of innovative/alternative 
approaches including assessment of target engagement selectivity in bromodomains inside cells in an 
unbiased fashion; covalent reversible or irreversible inhibitor design; development and application of 
sophisticated chemical biology approaches to enhance chemical probing; and finally, closer synergy between 
chemical and biological target validation.
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